The MOTION study: a randomized, Phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor

Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive neoplasm that occurs in the synovium of joints, bursae, or tendon sheaths and is caused by upregulation of the CSF1 gene. Vimseltinib is an oral switch-control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit the CSF1 receptor. Here, we describe the rationale and design for the Phase III MOTION trial (), which aims to evaluate the efficacy and safety of vimseltinib in participants with TGCT not amenable to surgical resection. In Part 1, participants are randomized to receive vimseltinib 30 mg twice weekly or matching placebo for = 24 weeks. Part 2 is a long-term treatment phase in which participants will receive open-label vimseltinib.